{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '66', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'participate for the full duration of the study, or it is not in the best interest of the', 'participant to participate, in the opinion of the treating investigator.', '26. Has had major surgery within 3 weeks prior to first dose of study intervention. Note:', 'Adequate wound healing after major surgery must be assessed clinically, independent of', 'time elapsed for eligibility.', '27. Has pre-existing >Grade 3 gastrointestinal or nongastrointestinal fistula.', '5.3', 'Lifestyle Considerations', '5.3.1', 'Meals and Dietary Restrictions', 'Participant should maintain a normal diet unless modifications are required to manage an AE,', 'such as diarrhea, nausea, or vomiting.', '5.3.2', 'Contraception', 'Based on its mechanism of action, lenvatinib can cause fetal harm when administered to a', 'pregnant woman. Lenvatinib may also result in reduced fertility in females of reproductive', 'potential and may result in damage to male reproductive tissues leading to reduced fertility of', 'unknown duration. In animal reproduction studies, oral administration of lenvatinib during', 'organogenesis at doses below the recommended human dose resulted in embryotoxicity,', 'fetotoxicity, and teratogenicity in rats and rabbits.', 'Participants should be informed that taking the study intervention may involve unknown', 'risks to the fetus (unborn baby) if pregnancy were to occur during the study. To participate in', 'the study, WOCBP must adhere to the contraception requirement (Appendix 5) from the day', 'of study intervention initiation throughout the study period up to 120 days post', 'pembrolizumab or 30 days post lenvatinib/matching placebo, whichever occurs last. If there', 'is any question that a WOCBP will not reliably comply with the requirements for', 'contraception, that participant should not be entered into the study.', '5.3.3', 'Pregnancy', 'If a participant inadvertently becomes pregnant while on study intervention, the participant', 'will be immediately discontinued from study intervention. The site will contact the', \"participant at least monthly and document the participant's status until the pregnancy has\", 'been completed or terminated. The outcome of the pregnancy will be reported to the Sponsor', 'without delay and within 24 hours if the outcome is an SAE (eg, death, abortion, congenital', 'anomaly, or other disabling or life-threatening complication to the mother or newborn). The', 'study investigator will make every effort to obtain permission to follow the outcome of the', 'pregnancy and report the condition of the fetus or newborn to the Sponsor. If a male', 'participant impregnates a female partner, the study personnel at the site must be informed', 'immediately, and the pregnancy must be reported to the Sponsor and followed as described', 'in Section 8.4.5.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '67', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '5.3.4', 'Use in Nursing Women', 'It is unknown whether lenvatinib or pembrolizumab is excreted in human milk. Since many', 'drugs are excreted in human milk and because of the potential for serious adverse reactions', 'in the nursing infant, participants who are breastfeeding are not eligible for enrollment.', '5.4', 'Screen Failures', 'Screen failures are defined as participants who consent to participate in the clinical study, but', 'are not subsequently randomized in the study. A minimal set of screen failure information is', 'required to ensure transparent reporting of screen failure participants to meet the', 'Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to', 'respond to queries from regulatory authorities. Minimal information includes demography,', 'screen failure details, eligibility criteria, and any AEs or SAEs meeting reporting', 'requirements as outlined in the data entry guidelines.', '5.5', 'Participant Replacement Strategy', 'A participant who discontinues from study intervention will not be replaced.', '6', 'STUDY INTERVENTION', 'NOTE: As of Amendment 007-06, lenvatinib and matching placebo have been removed', 'from the study; the portions of this section referring to these treatments are no longer', 'applicable. This section has been updated accordingly.', 'Study intervention is defined as any investigational intervention(s), marketed product(s)', 'placebo, or medical device(s) intended to be administered to a study participant according to', 'the study protocol.', 'Clinical supplies (pembrolizumab ) will be packaged to support enrollment as required.', 'Clinical supplies will be affixed with a clinical label in accordance with regulatory', 'requirements.', '6.1', 'Study Intervention(s) Administered', 'The study interventions to be used in this study are outlined in Table 2.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}